O'Connor Daniel S, Wall Nathan R, Porter Andrew C G, Altieri Dario C
Boyer Center for Molecular Medicine, Yale University School of Medicine, 295 Congress Avenue, New Haven, Connecticut 06536, USA.
Cancer Cell. 2002 Jul;2(1):43-54. doi: 10.1016/s1535-6108(02)00084-3.
A checkpoint surveying the entry into mitosis responds to defects in spindle microtubule assembly/stability. This has been used to trigger apoptosis in cancer cells, but how the spindle checkpoint couples to the cell survival machinery has remained elusive. Here, we report that microtubule stabilization engenders a survival pathway that depends on elevated activity of p34(cdc2) kinase and increased expression of the apoptosis inhibitor and mitotic regulator, survivin. Pharmacologic, genetic, or molecular ablation of p34(cdc2) kinase after microtubule stabilization resulted in massive apoptosis independent of p53, suppression of tumor growth, and indefinite survival without toxicity in mice. By ablating this survival checkpoint, inhibitors of p34(cdc2) kinase could safely improve the efficacy of microtubule-stabilizing agents used to treat common cancers.
一个监测进入有丝分裂过程的关卡会对纺锤体微管组装/稳定性的缺陷作出反应。这已被用于触发癌细胞的凋亡,但纺锤体关卡如何与细胞存活机制耦合仍不清楚。在此,我们报告微管稳定会产生一条依赖于p34(cdc2)激酶活性升高以及凋亡抑制剂和有丝分裂调节因子survivin表达增加的存活途径。微管稳定后对p34(cdc2)激酶进行药理学、遗传学或分子层面的去除会导致大量不依赖p53的凋亡、肿瘤生长受抑制以及小鼠无毒性的无限期存活。通过消除这个存活关卡,p34(cdc2)激酶抑制剂可安全地提高用于治疗常见癌症的微管稳定剂的疗效。